

Alfredo Adã;n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1879832/publications.pdf>

Version: 2024-02-01

111
papers

2,898
citations

201674

27
h-index

206112

48
g-index

113
all docs

113
docs citations

113
times ranked

2572
citing authors

#	ARTICLE	IF	CITATIONS
1	Spontaneous resolution of inflammatory epiretinal membrane: Case series and review of the literature. <i>European Journal of Ophthalmology</i> , 2023, 33, NP10-NP14.	1.3	2
2	Presumed tuberculosis-related scleritis. <i>British Journal of Ophthalmology</i> , 2023, 107, 495-499.	3.9	3
3	Intravitreal fluocinolone acetonide implant for the treatment of persistent post-surgical cystoid macular edema in vitrectomized eyes. <i>European Journal of Ophthalmology</i> , 2023, 33, NP23-NP27.	1.3	9
4	Clinical Features and Outcomes of Tubulointerstitial Nephritis and Uveitis Syndrome in Spain and Portugal: The IBERTINU Project. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 286-291.	1.8	7
5	Paracentral acute middle maculopathy after uneventful ocular surgery with local anaesthetic blocks. <i>Eye</i> , 2022, 36, 219-227.	2.1	8
6	Vogt-Koyanagi-Harada disease in Spain. <i>European Journal of Ophthalmology</i> , 2022, 32, 1547-1554.	1.3	2
7	CHARACTERIZING COVID-19-RELATED RETINAL VASCULAR OCCLUSIONS. <i>Retina</i> , 2022, 42, 465-475.	1.7	14
8	Consensus-based recommendations for optical coherence tomography angiography reporting in uveitis. <i>British Journal of Ophthalmology</i> , 2022, , bjophthalmol-2021-320021.	3.9	4
9	Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus Report 2: Diabetic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 197.	2.4	5
10	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 2022, 31, 1344-1354.	1.6	4
11	Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1591-1598.	1.8	1
12	Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. <i>Ophthalmology</i> , 2021, 128, 899-909.	5.2	25
13	Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients. <i>Journal of Rheumatology</i> , 2021, 48, 741-750.	2.0	17
14	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	6.5	23
15	Uveitic macular edema response to intravitreal dexamethasone implant is independent of optical coherence tomography findings. <i>International Ophthalmology</i> , 2021, 41, 787-796.	1.4	0
16	Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 6-8.	1.8	5
17	Estándares de calidad para las Unidades de Atención Integral al paciente con uveítis de la Sociedad Española de Inflammaci3n Ocular (SEIO). <i>Medicina Clínica</i> , 2021, 156, 76-80.	0.6	2
18	Systemic contribution of inflammatory mediators to the severity of diabetic and uveitic macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 2695-2705.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Interlink between Inflammation and Oxidative Stress in Age-Related Macular Degeneration: Role of Complement Factor H. <i>Biomedicines</i> , 2021, 9, 763.	3.2	21
20	Challenges in Diabetic Macular Edema Management: An Expert Consensus Report. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 3183-3195.	1.8	15
21	Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus. Report 4: Glycated Haemoglobin. <i>Diagnostics</i> , 2021, 11, 1537.	2.6	6
22	RETROPUPILLARY IRIS-CLAW INTRAOCULAR LENS AND PARS PLANA VITRECTOMY IN APHAKIA MANAGEMENT. <i>Retina</i> , 2021, 41, 2048-2058.	1.7	4
23	Tocilizumab for the Treatment of Ocular Inflammatory Disease. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 2-5.	1.8	7
24	Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl- β -Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model. <i>Pharmaceutics</i> , 2021, 13, 1737.	4.5	7
25	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.8	4
26	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.8	17
27	Antituberculous Treatment Itself Might Prevent Visual Impairment in Presumed Tuberculosis-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 103-110.	1.8	8
28	Long-Term Intravitreal Dexamethasone Implant Outcomes in Uveitis. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 228-237.	1.8	8
29	Utility of Ultra-Widefield Retinal Imaging in the Follow-up and Management of Patients with Cytomegalovirus Retinitis. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 659-664.	1.8	1
30	Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach. <i>European Journal of Ophthalmology</i> , 2020, 30, 1042-1052.	1.3	18
31	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. <i>Autoimmunity Reviews</i> , 2020, 19, 102429.	5.8	197
32	Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes. <i>BMC Ophthalmology</i> , 2020, 20, 443.	1.4	10
33	Systemic Regulatory T Cells and IL-6 as Prognostic Factors for Anatomical Improvement of Uveitic Macular Edema. <i>Frontiers in Immunology</i> , 2020, 11, 579005.	4.8	8
34	<p><sup>Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN[®]) and Follow-Up Considerations/Recommendations</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 2091-2107.	1.8	9
35	Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus. Report 1: Diabetic Retinopathy. <i>Translational Vision Science and Technology</i> , 2020, 9, 34.	2.2	22
36	Optimization of Diabetic Macular Edema Management in the Real World: A Model of Excellence in Retina Units: The EMUREX Initiative. <i>Ophthalmologica</i> , 2020, 243, 379-390.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Activation of C-reactive protein proinflammatory phenotype in the blood retinal barrier in vitro: implications for age-related macular degeneration. <i>Aging</i> , 2020, 12, 13905-13923.	3.1	12
38	Bilateral Acute Retinal Necrosis: Clinical Features and Outcomes in a Multicenter Study. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 1090-1098.	1.8	23
39	Recent progress in the treatment of uveitic macular edema. <i>Expert Review of Ophthalmology</i> , 2019, 14, 227-236.	0.6	6
40	Shear stress modulates inner blood retinal barrier phenotype. <i>Experimental Eye Research</i> , 2019, 187, 107751.	2.6	17
41	Aqueous Humour Cytokine Changes with Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 1203-1210.	1.8	7
42	Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 2307-2314.	1.9	7
43	Modelling Macular Edema: The Effect of IL-6 and IL-6R Blockade on Human Blood-Retinal Barrier Integrity In Vitro. <i>Translational Vision Science and Technology</i> , 2019, 8, 32.	2.2	30
44	Multimodal retinal imaging of familial amyloid polyneuropathy. <i>Ophthalmic Genetics</i> , 2019, 40, 407-420.	1.2	13
45	Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. <i>American Journal of Ophthalmology</i> , 2019, 200, 85-94.	3.3	81
46	Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis. <i>PLoS ONE</i> , 2019, 14, e0210799.	2.5	13
47	Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases. <i>Arthritis and Rheumatology</i> , 2019, 71, 2081-2089.	5.6	74
48	Angiography and En Face Optical Coherence Tomography Findings in Acute Syphilitic Posterior Placoid Chorioretinopathy. <i>Case Reports in Ophthalmology</i> , 2019, 10, 165-171.	0.7	12
49	Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema. , 2019, 60, 1336.		23
50	THU0573...COMPLICATIONS AND ACTIVITY OF UVEITIS IN A MULTIDISCIPLINARY REFERENCE UNIT IN THE NORTH OF SPAIN. , 2019, , .		0
51	Clinical Features of Primary and Systemic Metastatic Intraocular Lymphomas in Spanish Patients. <i>Journal of Ophthalmology</i> , 2019, 2019, 1-9.	1.3	9
52	Evaluation of microvascular changes in the perifoveal vascular network using optical coherence tomography angiography (OCTA) in type I diabetes mellitus: a large scale prospective trial. <i>BMC Medical Imaging</i> , 2019, 19, 91.	2.7	12
53	Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 273-278.	1.9	7
54	Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world. <i>PLoS ONE</i> , 2019, 14, e0209997.	2.5	23

#	ARTICLE	IF	CITATIONS
55	Ultrawide Field Imaging and OCT Angiography in Late-Onset Chloroquine Retinopathy. <i>Journal of Vitreoretinal Diseases</i> , 2018, 2, 58-60.	0.7	0
56	Clinical Decision-Making when Treating Diabetic Macular Edema Patients with Dexamethasone Intravitreal Implants. <i>Ophthalmologica</i> , 2018, 240, 61-72.	1.9	14
57	Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. <i>Ophthalmology</i> , 2018, 125, 1075-1087.	5.2	134
58	Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. <i>Ophthalmology</i> , 2018, 125, 1444-1451.	5.2	50
59	Bacillus Calmette-Guérin Infection and Cytotoxicity in the Retinal Pigment Epithelium. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 786-792.	1.8	7
60	TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA. <i>Retina</i> , 2018, 38, 1361-1370.	1.7	70
61	R&I. <i>Medicina Clínica</i> , 2018, 151, 336-337.	0.6	0
62	Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis. <i>Human Molecular Genetics</i> , 2018, 27, 4333-4343.	2.9	42
63	Novel Association of High C-Reactive Protein Levels and A69S at Risk Alleles in Wet Age-Related Macular Degeneration Women. <i>Frontiers in Immunology</i> , 2018, 9, 1862.	4.8	4
64	Behavior of hyperreflective foci in non-infectious uveitic macular edema, a 12-month follow-up prospective study. <i>BMC Ophthalmology</i> , 2018, 18, 179.	1.4	13
65	Repeatability and reproducibility of retinal and choroidal thickness measurements in Diabetic Macular Edema using Swept-source Optical Coherence Tomography. <i>PLoS ONE</i> , 2018, 13, e0200819.	2.5	14
66	C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration. <i>Frontiers in Immunology</i> , 2018, 9, 808.	4.8	42
67	Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 652-657.	0.8	12
68	Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. <i>Autoimmunity Reviews</i> , 2017, 16, 237-243.	5.8	25
69	New insights into the genetic component of non-infectious uveitis through an ImmunoChip strategy. <i>Journal of Medical Genetics</i> , 2017, 54, 38-46.	3.2	18
70	C-reactive protein isoforms differentially affect outer blood-retinal barrier integrity and function. <i>American Journal of Physiology - Cell Physiology</i> , 2017, 312, C244-C253.	4.6	16
71	New imaging techniques in retinal vasculitis. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 261-266.	0.2	3
72	Nuevas técnicas de imagen en vasculitis retinianas. <i>Medicina Clínica</i> , 2017, 149, 261-266.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Targeting interleukin-6 in autoimmune uveitis. <i>Autoimmunity Reviews</i> , 2017, 16, 1079-1089.	5.8	53
74	In Response to: Deuter CM, Zierhut M, Igney-Oertel A, et al. Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 221-222.	1.8	2
75	Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 668-675.	5.6	129
76	Peripheral blood metabolic and inflammatory factors as biomarkers to ocular findings in diabetic macular edema. <i>PLoS ONE</i> , 2017, 12, e0173865.	2.5	25
77	Certolizumab Pegol, a New Anti-TNF- α in the Armamentarium against Ocular Inflammation. <i>Ocular Immunology and Inflammation</i> , 2016, 24, 1-6.	1.8	41
78	Complement factor H binding of monomeric C-reactive protein downregulates proinflammatory activity and is impaired with at risk polymorphic CFH variants. <i>Scientific Reports</i> , 2016, 6, 22889.	3.3	54
79	Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 2183-2188.	2.0	99
80	SAFETY AND EFFICACY OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN THE MANAGEMENT OF MACULAR EDEMA SECONDARY TO INFECTIOUS UVEITIS. <i>Retina</i> , 2016, 36, 1778-1785.	1.7	27
81	Interleukin-22 serum levels are elevated in active scleritis. <i>Acta Ophthalmologica</i> , 2016, 94, e395-9.	1.1	13
82	Elevated Serum Immune Mediators and Subclinical Inflammation in HLA-A29-associated Birdshot Chorioretinopathy. <i>Ocular Immunology and Inflammation</i> , 2016, 24, 647-652.	1.8	14
83	Evaluation of Objective Vitritis Grading Method Using Optical Coherence Tomography: Influence of Phakic Status and Previous Vitrectomy. <i>American Journal of Ophthalmology</i> , 2016, 161, 172-180.e4.	3.3	31
84	The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S34-S40.	0.8	10
85	Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization. <i>Acta Ophthalmologica</i> , 2015, 93, 561-567.	1.1	104
86	Uveitic macular oedema after treatment with vemurafenib. <i>Acta Ophthalmologica</i> , 2015, 93, e686-7.	1.1	16
87	Specific association of IL17A genetic variants with panuveitis. <i>British Journal of Ophthalmology</i> , 2015, 99, 566-570.	3.9	6
88	Clinical Course of a Presumed Metastatic Uveal Melanoma to the Contralateral Choroid. <i>Seminars in Ophthalmology</i> , 2015, 30, 417-419.	1.6	2
89	Immunostaining images of vitreous transthyretin amyloid. <i>Canadian Journal of Ophthalmology</i> , 2015, 50, 384-387.	0.7	6
90	Proinflammatory Cytokines and C-Reactive Protein in Uveitis Associated with Behçet's Disease. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	3.0	30

#	ARTICLE	IF	CITATIONS
91	Long-Term Effects of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema. <i>Ophthalmology</i> , 2014, 121, 2380-2386.	5.2	83
92	Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 163-164.	1.9	23
93	Multicenter Study of Intravitreal Dexamethasone Implant in Noninfectious Uveitis: Indications, Outcomes, and Reinjection Frequency. <i>American Journal of Ophthalmology</i> , 2014, 158, 1136-1145.e5.	3.3	109
94	Anti-TNF- α therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. <i>Rheumatology</i> , 2014, 53, 2223-2231.	1.9	109
95	An old disease in an atypical place. <i>Survey of Ophthalmology</i> , 2014, 59, 660-663.	4.0	6
96	Tocilizumab treatment for refractory uveitis-related cystoid macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 2627-2632.	1.9	103
97	Tocilizumab treatment for recalcitrant uveitic macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 2249-2250.	1.9	21
98	Behçet Disease-associated Uveitis Successfully Treated with Golimumab. <i>Ocular Immunology and Inflammation</i> , 2013, 21, 160-162.	1.8	71
99	DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF UVEITIC PERSISTENT CYSTOID MACULAR EDEMA IN VITRECTOMIZED PATIENTS. <i>Retina</i> , 2013, 33, 1435-1440.	1.7	85
100	Biologic drugs in noninfectious uveitis: an update. <i>Expert Review of Ophthalmology</i> , 2013, 8, 501-516.	0.6	2
101	Cytologic identification of <i>Toxoplasma gondii</i> from subretinal aspirate. <i>Acta Ophthalmologica</i> , 2012, 90, 392-393.	1.1	4
102	Intravitreal bevacizumab injection for peripheral exudative hemorrhagic chorioretinopathy. <i>Japanese Journal of Ophthalmology</i> , 2011, 55, 425-427.	1.9	16
103	Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. <i>International Ophthalmology</i> , 2010, 30, 577-581.	1.4	42
104	Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. <i>European Journal of Ophthalmology</i> , 2009, 19, 1039-1043.	1.3	36
105	Explantation of intraocular lenses in children with juvenile idiopathic arthritis-associated uveitis. <i>Journal of Cataract and Refractive Surgery</i> , 2009, 35, 603-605.	1.5	20
106	Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. <i>European Journal of Ophthalmology</i> , 2009, 19, 1039-43.	1.3	12
107	Optical coherence tomography findings and management of sub-internal limiting membrane haemorrhage. <i>Acta Ophthalmologica</i> , 2008, 86, 582-583.	1.1	3
108	INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION AS PRIMARY TREATMENT OF INFLAMMATORY CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2007, 27, 1180-1186.	1.7	72

#	ARTICLE	IF	CITATIONS
109	Successful Treatment With Infliximab in a Patient With Diffuse Subretinal Fibrosis Syndrome. American Journal of Ophthalmology, 2007, 143, 533-534.	3.3	38
110	Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1873-1875.	1.9	29
111	Use of Steroids and Heparin to Treat Retinal Arterial Occlusion in Mediterranean Spotted Fever. Journal of Infectious Diseases, 1988, 158, 1139-1140.	4.0	15